Background: Common cold is the most common disease which mainly affects the upper respiratory system. It is caused by viral or, in a small percentage, by bacterial infections. Current therapy options focus on symptomatic relief of the disease such as nasal saline irrigation, an easy-to-apply, comfortable, non-toxic method. In this study, a novel hypertonic seawater solution enriched with hyaluronic acids, eucalyptus oil, copper and manganese salts, Stérimar Stop & Protect Cold and Flu (SSPCF), has been investigated with respect to efficacy against viral and microbial infections.
Introduction
Common cold (viral acute rhinosinusitis) is an upper respiratory tract infection which primarily affects the nasal respiratory mucosa and mainly causes nasal blockage/obstruction/congestion for a duration of less than 10 days (1) . Children and adults are estimated to suffer from up to 5 and 3 colds per year, respectively (2) , which also causes time-off from school or work, translating to an economic and social burden (3) . Rhinovirus infections are the main cause of common cold cases and lead to epithelial barrier dysfunction without causing cell death and enhance the invasion of bacteria which may cause bacterial superinfections (4) (5) (6) . When common cold symptoms worsen after 5 days or persist for more than ten days up to 12 weeks, the disease is called post-viral acute rhinosinusitis. A small subgroup of the postviral rhinosinusitis (estimated around 0.5-2.0%) (7) is caused by bacteria (mainly S. pneumoniae, H. influenzae, M. catarrhalis and S. aureus) to develop acute bacterial rhinosinusitis (1) .
Treatment options for common cold concentrate around symptomatic relief (8) , among which, nasal irrigation (NI) with Poster Presentation: The outcomes of this work have been presented as a poster at the "27th Congress of the European Rhinologic Society" in London (United Kingdom), on April 2018. saline solution is recommended as a safe, easy-to-use, comfortable and not-expensive method (9) . In addition, NI has been shown to, at least partially, remove viruses and inflammatory mediators, and inhibit viral replication in the nasal cavities in upper respiratory tract infections (10) . Saline NI applications also have been shown to decrease sinus medicine use in 35% of patients (11) . Ragab et al. showed that there are no differences in nasal and total symptom scores of children with common cold who received saline NI combined with amoxicillin or placebo treatment. In the placebo group, children presented less adverse effects, suggesting that the saline NI alone (no antibiotic) is not only sufficient but also safer (12) . Thus, improving the NI formulations may improve the symptomatic relief outcomes with a better safety profile and contribute to the decrease in the irrational use of medicinal products.
Hypertonic solutions are frequently used for NI and, due to their high salt concentration, were claimed to reduce oedema by draining water from surrounding tissues through diffusion of osmolar gradients (13) , and have been shown to be effective in the elimination of nasal congestion in chronic rhinosinusitis (14) .
In addition, in vitro studies have shown that hypertonic saline solutions are safe to use on nasal tissues as they do not compromise nasal epithelial integrity (15) . 
Materials and Methods

Biological model (test system) used for the in vitro studies
The in vitro assays were performed in a 3D reconstituted human nasal epithelium model, MucilAir™ (Epithelix Sàrl, Geneva, Switzerland) for its great potential as a model to test respiratory sensitizers (16, 17) . For maintenance, inserts were incubated in 500µl of MucilAir™ culture medium in a CO 2 incubator (37ºC, 5% CO 2 , 100% humidity, Heracell).
Viral load assays
Replication of HRV-A16 has been previously shown to be successful in the MucilAir™ model in which the viral RNA load reaches a maximum in 24-48 hours after infection (18) . In order to evaluate the effect of SSPCF on viral load, both pre-and posttreatment approaches were followed.
Effect of treatment prior to HRV-A16 infection
HRV-A16 virus stocks were prepared in HeLa Ohio and Vero cells as previously described (19) . Prior to viral inoculation, tissues were treated 1 hour with saline (0.9%) (in triplicate) or SSPCF (n=3) or 5mM Rupintrivir (n=2, Santa Cruz Biotechnology Inc., Dallas, Texas, United States), a potent and irreversible inhibitor of human rhinovirus 3C protease (20) . At 0h, tissues were apically inoculated with 100µl HRV-A16 (2.8x10 6 RNA copies /ml). After 3.5 hours of incubation at 34ºC, supernatants were aspirated, and tissues were rinsed. 200µl of MucilAir™ culture medium was added for 20 minutes and the virus were harvested. The epithelia were further cultured at the air-liquid interface. At 24h, viral load was collected the same way. The viral load was quantified with Entero/Ge/08 one-step real-time PCR as previously described (19, 21) . 
Effect of treatment after HRV-A16 infection
Results
Effect on viral replication
Results of 1-hour SSPCF pre-treatment before HRV-A16 infection showed that viral replication was almost completely inhibited in this sample as compared to saline-treated control (99.78% inhibition, 2.05x10 7 vs 4.50x10 4 , respectively ( Figure 1A) . The effect of SSPCF was similar to the effect of rupintrivir.
Results of the post-infection treatment (24 hours after infection)
showed that 24 hours of treatment (48 hours after infection) decreased the viral load compared to saline-treated control, reaching up to 60% inhibition (6.73x10 8 vs. 2.70x10 8 copies RNA/ ml) ( Figure 1B) .
Effect on bacterial growth
The efficacy of SSPCF against S. aureus was tested by monitoring of bacterial growth at 1, 3 and 24 hours after treatment. As shown in Figure 2 , treatment with SSPCF has an anti-bacterial effect compared to untreated control (growth medium). Starting from as early as one hour after treatment the S. aureus colony forming unit counts decreased from over 1.0x10 6 to 0 and is maintained throughout the course of the experiment (24h). that the increase was more than 3-fold ( Figure 3B, p<0.001 ).
Effect on the phagocytic activity of nasal epithelial cells
Discussion
The present study aimed to test the efficacy of a hypertonic seawater solution enriched with hyaluronic acids, eucalyptus oil as well as copper and manganese salts against pathogens such as human rhinovirus which are known to cause common cold (4, 5) and S. aureus which is an important pathogen in respiratory infections (22) , in an in vitro model of reconstituted human nasal epithelium. Manganese has been shown to inhibit the anaphylactic histamine release (23) and reduces inflammatory response (24) . Hyaluronic acid increases tissue hydration and shortens healing time (25, 26) .
The model used in this study, MucilAir™ is composed of basal cells, ciliated cells and mucus cells in a proportion similar to
what one observes in vivo (27) . Moreover, MucilAir™ is functionally differentiated, conserves tissue integrity (TEER>200 W.cm 2 ) and also secretes mucus. The activity of the main epithelial ionic channels, such as CFTR, EnaC, Na/K ATPase, is preserved and the epithelia is shown to respond in a regulated and vectorial manner to the pro-inflammatory stimulus, TNF-a (27) . A large panel of Most importantly, MucilAir™ replicates the main function of the airway epithelial cells, the mucociliary clearance driven by synchronized cilia-beating, and has been successfully used for acute, long-term and chronic in vitro studies (16, 17, 28, 29) . Given that MucilAir™ is functionally robust and successfully mimics human nasal epithelium, it is important to conduct a clinical trial with SSPCF in order to demonstrate the safety and efficacy of it in in vivo settings.
At the performance level, treatment with SSPCF prior to HRV-A16 infection reduced viral load compared to saline-treated cells (almost 100%), as measured by viral RNA copy numbers, indicating the inhibition of rhinovirus replication. The reduction was similar to the one caused by treatment with rupintrivir, a well-known viral protease inhibitor (20) . 60% viral replication inhibition was also observed when treatment was performed after viral infection. Therefore, SSPCF has a prophylactic effect against HRV-A16 and is also effective when used post-infection (~100% and 60% inhibition, respectively).
In addition, efficacy of SSPCF in control of bacterial growth was also assessed. The results in Figure 1 show that, as early as 1 hour after treatment, SSPCF exerted anti-bacterial effect on S. aureus growth (complete inhibition), compared to untreated control cultures.
Respiratory epithelial cells orchestrate the immune defense response against incoming toxins and pathogens. Pathogen recognition pathways in epithelial cells can stimulate phagocytosis (30) . An increase in phagocytic activity was also observed upon treatment with SSPCF compared to treatment with saline solution. The performed assay employed IgG-FITC conjugated latex beads. It would be interesting to investigate whether there is an increase in phagocytosis of HRV-A16 or S. aureus via live cell imaging to confirm that the increase in phagocytic activity shown with fluorescent beads is contributing to an antimicrobial effect. Others have previously shown that primary nasal epithelial cells cultured in vitro in an air-liquid interface similar to the MucilAir™ model, are able to phagocyte other pathogens such as Aspergillus fumigatus (31) .
Upon colonizing the nose, S. aureus competes with the bacteria of the nasal microflora and has been shown to form a biofilm enabling other bacteria species to grow (32) . Biofilms provide bacteria with a protective environment against host defense which may lead to chronic diseases such as chronic rhinosinusitis (33) . In this regard, topical irrigation treatments, including nasal saline irrigation, have been shown to be effective in the elimination of biofilms both in animal and human chronic rhinosinusitis models as reviewed recently (34) . Therefore, the prevention of bacterial growth demonstrated in this in vitro study may be due to the partial or complete elimination of biofilm, or the prevention of its formation.
Conclusions
Overall, results of the present study support that in vitro, SSPCF is able to inhibit HRV-A16 replication and S. aureus growth, and SSPCF is effective in protecting the nasal epithelial tissues from viral and bacterial pathogens. In vitro tests presented in this study suggest that SSPCF has (i) an inhibitory effect on viral replication when applied pre-or post-infection by HRV A16, (ii) anti-bacterial effect on S. aureus; and (iii) phagocytosis-enhancing effect that could be useful against viruses and bacteria involved in common cold. Safety and efficacy evaluation of SSPCF in the clinical settings is needed to prove the beneficial effects of the formulation at the clinical level. 
